Сase Report of Acute Toxic Imatinib-induced Hepatitis in a Patient with Chronic Myeloid Leukemia, Sulfa Allergy, and Rheumatoid Arthritis.

Clicks: 268
ID: 59908
2018
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The introduction of imatinib has substantially changed the approaches to the therapy of chronic myeloid leukemia. However, this drug can cause hepatic failure and death in rare cases. This report describes a clinical case of acute, toxic imatinib-induced hepatitis in a 56-year-old woman with chronic myeloid leukemia and concomitant sulfa allergy and rheumatoid arthritis. The patient developed acute imatinib-induced hepatitis after three months of treatment with imatinib and three days after increasing the imatinib dosage from 400 mg per day to 600 mg per day, resolving within three months after imatinib discontinuation and prednisolone administration. This confirms the necessity of great caution during imatinib therapy and the monitoring of liver tests. Approximately 25 reports about clinical cases of imatinib-induced hepatitis have been published up to the present.
Reference Key
lopina2018asecureus Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lopina, Nataliia;Dyagil, Iryna;Hamov, Dmytro;Zhuravlyova, Larysa;Dmytrenko, Iryna;Lopin, Dmytro;Igor, Kuznetsov;
Journal Cureus
Year 2018
DOI 10.7759/cureus.3136
URL
Keywords
imatinib tyrosine kinase inhibitors acute liver failure chronic myeloid leukemia acute toxic hepatitis drug induced liver disease hormone therapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.